TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23123107

Group type: EXPERIMENTAL
Intervention: PCV13+TIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study: 21154012

Group type: EXPERIMENTAL
Intervention: Induced belief that failure was beyond control and unlikely to change (Experiment 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Induced belief that failure was within one's control and likely to change (Experiment 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mediation by self-efficacy
Number of subjects: 80
Study: 18201683

Group type: EXPERIMENTAL
Intervention: AquaLase
Number of subjects: 50

Group type: COMPARATOR
Intervention: NeoSoniX
Number of subjects: 50
Study: 16645372

Group type: EXPERIMENTAL
Intervention: Ibutilide pretreatment (0.01 mg/kg IV over 10 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immediate cardioversion with biphasic shock
Number of subjects: 50
Study: 14639195

Group type: EXPERIMENTAL
Intervention: 25% dextrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30% glucose
Number of subjects: 0
Study: 10522566

Group type: EXPERIMENTAL
Intervention: Asymmetrical biphasic shock (6.5/2.5 ms)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Symmetrical biphasic shock (3.0/3.0 ms)
Number of subjects: 19
Study: 7540892

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1951408

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg taken twice daily (n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Continued parenteral antibiotics (n = 53)
Number of subjects: 105
Study: 6970265

Group type: EXPERIMENTAL
Intervention: Haemoccult
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Haemastix
Number of subjects: 448
Study: 31368793

Group type: EXPERIMENTAL
Intervention: Randomized participants (n=25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Eligible individuals who declined to enroll (n=26)
Number of subjects: 51
Study: 27840104

Group type: EXPERIMENTAL
Intervention: High-power pose
Number of subjects: 247

Group type: COMPARATOR
Intervention: Neutral or low-power poses
Number of subjects: 247
Study: 25825336

Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 155
Study: 24374975

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Single-dose vemurafenib (960 mg)
Number of subjects: 15
Study: 22892064

Group type: EXPERIMENTAL
Intervention: MBCP-FS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Autologous bone (mixed with Bio-Oss)
Number of subjects: 96
Study: 19574322

Group type: EXPERIMENTAL
Intervention: Nurse-led comprehensive geriatric evaluation and management (GEM) programme
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 17726081

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 15264650

Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 22
Study: 11216961

Group type: EXPERIMENTAL
Intervention: Self-reported periodontal disease
Number of subjects: 22037
Study: 9735884

Group type: EXPERIMENTAL
Intervention: Forearm capillary filtration coefficient (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Calf capillary filtration coefficient (group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Forearm capillary filtration coefficient (group B)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Calf capillary filtration coefficient (group B)
Number of subjects: 22
Study: 9208293

Group type: EXPERIMENTAL
Intervention: Pneumatic pedal compression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (posterior splint, ice, and elevation)
Number of subjects: 30
Study: 2007745

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg t.i.d. for 12 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 6122970

Group type: EXPERIMENTAL
Intervention: Once-monthly rifampicin (1,200 mg in a single oral dose) plus daily dapsone (50 mg/day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Daily rifampicin (450 mg/day) plus daily dapsone (50 mg/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Once-monthly rifampicin (1,200 mg in a single oral dose)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Daily rifampicin (450 mg/day)
Number of subjects: 93
Study: 31330810

Group type: EXPERIMENTAL
Intervention: Starch‐ and sucrose‐reduced diet (SSRD) for 4 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ordinary eating habits (control group)
Number of subjects: 105
Study: 28867126

Group type: EXPERIMENTAL
Intervention: Early Ventricular Tachycardia/Ventricular Fibrillation (VT/VF)
Number of subjects: 3602

Group type: COMPARATOR
Intervention: No Early Ventricular Tachycardia/Ventricular Fibrillation (VT/VF)
Number of subjects: 3602
Study: 25297492

Group type: EXPERIMENTAL
Intervention: Laparoscopic partial nephrectomy (LPN)
Number of subjects: 280
Study: 23702209

Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 115
Study: 21514398

Group type: EXPERIMENTAL
Intervention: Bimosiamose (10 mg bid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18461895

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 954

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 954
Study: 16921033

Group type: EXPERIMENTAL
Intervention: Early thoracic radiotherapy (TRT) administered concurrently in the second cycle
Number of subjects: 325

Group type: COMPARATOR
Intervention: Late thoracic radiotherapy (TRT) administered concurrently with the sixth cycle
Number of subjects: 325
Study: 12835516

Group type: EXPERIMENTAL
Intervention: Combined therapy (doxorubicin + DES)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 162
Study: 10870148

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with or without transpedicular fixation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 111
Study: 8878218

Group type: EXPERIMENTAL
Intervention: 5 micrograms Engerix-B vaccine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 10 micrograms Engerix-B vaccine
Number of subjects: 193
Study: 2059673

Group type: EXPERIMENTAL
Intervention: Olsalazine (OLZ) tablets (1g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olsalazine (OLZ) capsules (1g)
Number of subjects: 9
Study: 6366141

Group type: EXPERIMENTAL
Intervention: Alternating combination chemotherapy (vincristine, doxorubicin, alkylating agents, and prednisone)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Alternating combination chemotherapy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with levamisole
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional chemotherapy (melphalan and prednisone)
Number of subjects: 237
Study: 31886629

Group type: EXPERIMENTAL
Intervention: 100 million ASCs plus intralesional fibrin glue (group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intralesional fibrin glue (group B)
Number of subjects: 57
Study: 30669280

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (1000 IU/day from 14 weeks gestation)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 29459021

Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300

Group type: COMPARATOR
Intervention: Suture repair
Number of subjects: 300
Study: 26417061

Group type: EXPERIMENTAL
Intervention: 90-day use of Vaughan Williams class I or III antiarrhythmic drugs (AAD)
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Control group (no AAD)
Number of subjects: 2038
Study: 24614387

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day of vitamin D3 plus a daily multivitamin containing 400 IU of vitamin D3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (placebo plus a multivitamin containing 400 IU of vitamin D3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21410548

Group type: EXPERIMENTAL
Intervention: Intervention (INT): Educational intervention on hydration, including a lecture on hydration and improved water accessibility during training, dining, and resting areas.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (CON): No specific intervention, free access to fluids.
Number of subjects: 92
Study: 19175929

Group type: EXPERIMENTAL
Intervention: AVI-014 at 4 mcg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AVI-014 at 8 mcg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AVI-014
Number of subjects: 24

Group type: COMPARATOR
Intervention: filgrastim (Neupogen, Amgen) at 4 mcg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: filgrastim (Neupogen, Amgen) at 8 mcg/kg
Number of subjects: 24
Study: 17984247

Group type: EXPERIMENTAL
Intervention: Flutamide-metformin (62.5 mg/day + 850 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metformin alone (850 mg/day)
Number of subjects: 32
Study: 15320689

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 22
Study: 12392863

Group type: COMPARATOR
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9524012

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pilsicainide
Number of subjects: 22
Study: 8887604

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg administered twice a day via a Diskhaler for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2818824

Group type: EXPERIMENTAL
Intervention: Extended massage (60 seconds)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard massage (30 seconds)
Number of subjects: 20
Study: 1158630

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30887960

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (mock acupuncture)
Number of subjects: 30
Study: 28623628

Group type: EXPERIMENTAL
Intervention: Software-based preference assessment in addition to the brochure about prostate cancer treatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Education with a brochure about prostate cancer treatment
Number of subjects: 122
Study: 25487185

Group type: EXPERIMENTAL
Intervention: Topical application of toluidine blue with micropipette followed by 630-nm GaAlAs laser (power density: 10 mW/cm²) during two visits
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mouthwash diluted with dexamethasone (tab 0/5 in 5 ml water) for 5 min, followed by rinsing with nystatin 100,000 units for 5 min
Number of subjects: 25
Study: 24010987

Group type: EXPERIMENTAL
Intervention: 4% prilocaine plain, 5 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine, 2.5 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 90
Study: 21396408

Group type: EXPERIMENTAL
Intervention: Intranasal trivalent live attenuated influenza vaccine (LAIV)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated vaccine (TIV)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Family history of asthma
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 99
Study: 19302559

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone at first relapse
Number of subjects: 0
Study: 16485884

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin phosphate 1% gel with dimethicone and glycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination use with topical retinoid
Number of subjects: 0
Study: 15465745

Group type: EXPERIMENTAL
Intervention: 100% portion size served
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125% portion size served
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150% portion size served
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (previous week's consumption)
Number of subjects: 0
Study: 11534890

Group type: EXPERIMENTAL
Intervention: Budesonide (100 microg or 400 microg) twice daily plus formoterol 9 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide (100 microg or 400 microg) twice daily
Number of subjects: 0
Study: 9324366

Group type: EXPERIMENTAL
Intervention: 40 ml of prilocaine 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30 ml of prilocaine 1% plus 10 ml bupivacaine 0.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 ml of prilocaine 1% plus 20 ml bupivacaine 0.5%
Number of subjects: 90
Study: 8233733

Group type: EXPERIMENTAL
Intervention: Silver nitrate eye prophylaxis
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Erythromycin eye prophylaxis
Number of subjects: 630

Group type: COMPARATOR
Intervention: No eye prophylaxis
Number of subjects: 630
Study: 2881572

Group type: EXPERIMENTAL
Intervention: 2 mg ethyl loflazepate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6 mg ethyl loflazepate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29710111

Group type: EXPERIMENTAL
Intervention: Systematic cross‐checking between emergency physicians, 3 times a day
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1680
Study: 27151508

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Filtered air (FA) exposure for 2 hours (control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Co-exposure to DE and allergen
Number of subjects: 17
Study: 24112602

Group type: COMPARATOR
Intervention: US-BT1 brachytherapy technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: US-BT2 brachytherapy technique
Number of subjects: 0
Study: 22390720

Group type: EXPERIMENTAL
Intervention: Immediate second resection of the tumor bed after complete TUR
Number of subjects: 126

Group type: COMPARATOR
Intervention: No immediate second resection of the tumor bed
Number of subjects: 126
Study: 20805273

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 26
Study: 18579510

Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone every other day for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15920748

Group type: EXPERIMENTAL
Intervention: Dietary counseling with regular foods (group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Usual diet plus supplements (group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intake ad lib (group 3)
Number of subjects: 75
Study: 11833023

Group type: EXPERIMENTAL
Intervention: MultiGym
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ElasticGym
Number of subjects: 17
Study: 10410790

Group type: EXPERIMENTAL
Intervention: Electromyography in patients without neuromuscular disorders
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electromyography in patients with neuromuscular disorders
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group of healthy examinees
Number of subjects: 75
Study: 7749435

Group type: EXPERIMENTAL
Intervention: 252 mg quinacrine pellets
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 324 mg quinacrine pellets
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100 mg quinacrine (previously reported)
Number of subjects: 33
Study: 1703909

Group type: EXPERIMENTAL
Intervention: rh-EPO at a dose of 3 x 80 U/kg body weight per week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rh-EPO
Number of subjects: 20
Study: 850695

Group type: EXPERIMENTAL
Intervention: Proprioceptive facilitation patterning
Number of subjects: 42

Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Target throwing
Number of subjects: 42
Study: 31190494

Group type: EXPERIMENTAL
Intervention: Articular needling at Sifeng (EX-UE 10)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study: 28724962

Group type: EXPERIMENTAL
Intervention: 7-transcript signature
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 10-transcript signature
Number of subjects: 47
Study: 25755034

Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study: 23863036

Group type: EXPERIMENTAL
Intervention: Less oxidized omega-3 oil pills
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Highly oxidized omega-3 oil pills
Number of subjects: 52

Group type: COMPARATOR
Intervention: No capsules (control group)
Number of subjects: 52
Study: 21680159

Group type: EXPERIMENTAL
Intervention: Operator-driven quantitative approach (visual inspection and manual labeling)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fully automated quantitative approach (image segmentation, voxel intensity thresholding, seed growing)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both approaches (operator-driven and fully automated)
Number of subjects: 28
Study: 18665696

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Trauma Counseling (TC)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Monitoring Group (MG)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: NET
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: NET and TC
Number of subjects: 277
Study: 17067376

Group type: EXPERIMENTAL
Intervention: Educational intervention (3 wards)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (2 wards)
Number of subjects: 167
Study: 12866115

Group type: EXPERIMENTAL
Intervention: XeCl excimer TMLR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Optimal cardiac medication (controls)
Number of subjects: 30
Study: 10831267

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 76
Study: 9168460

Group type: EXPERIMENTAL
Intervention: Menhaden oil (6.26 g, n-3 fatty acids) with vitamin E (900 IU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Menhaden oil (6.26 g, n-3 fatty acids)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Menhaden oil (6.26 g, n-3 fatty acids) with placebo instead of vitamin E
Number of subjects: 80

Group type: COMPARATOR
Intervention: Olive oil with vitamin E (900 IU)
Number of subjects: 80
Study: 1550166

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline pump
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 725
Study: 3929308

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 32
Study: 30808668

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches + 18 mg/mL nicotine e‐cigarette
Number of subjects: 1809

Group type: COMPARATOR
Intervention: 21 mg nicotine patches + nicotine free e‐cigarette
Number of subjects: 1809

Group type: COMPARATOR
Intervention: 21 mg nicotine patches
Number of subjects: 1809
Study: 29521661

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 40-mg chloroprocaine 1%
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia with sufentanil, propofol and a laryngeal mask
Number of subjects: 50
Study: 27354234

Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Packaged Cognitive‐Behavioral Treatment (PCBT)
Number of subjects: 193
Study: 25256624

Group type: EXPERIMENTAL
Intervention: Bilateral aspherical toric IOL implantation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bilateral aspherical control IOL implantation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 86
Study: 23075518

Group type: EXPERIMENTAL
Intervention: NeuroFlo™ device treatment
Number of subjects: 358

Group type: COMPARATOR
Intervention: Not treated with NeuroFlo™ device
Number of subjects: 358
Study: 20186137

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2153
Study: 17032098

Group type: COMPARATOR
Intervention: TLFB interview
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Basic BMI
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Enhanced BMI
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 509
Study: 12743579

Group type: EXPERIMENTAL
Intervention: Celecoxib (10, 30, or 100 mg in suspension)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg administered as two 200-mg doses 2 hours apart)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10659016

Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty
Number of subjects: 38
Study: 9295819

Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 micrograms/kg, 20‐mL bolus) followed by continuous infusion (3.5 micrograms/kg/hr) for 72 hrs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (20‐mL bolus) followed by continuous infusion (20 mL for 30 mins)
Number of subjects: 10
Study: 8441895

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg o.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 3729492

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Droperidol (DP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63